Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.34 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.33 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.31 |
| ▸ | SELL | P14151 | 6/20 | 0.31 |
| ▸ | SELP | P16109 | 6/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL712212 | 1.00 | L3MBTL1 (0.36) | L3MBTL1FUCA1AMY1ASYNJ2NR1H3 | |
| SCHEMBL26824204 | 1.00 | L3MBTL1 (0.36) | L3MBTL1FUCA1AMY1ASYNJ2NR1H3 | |
| SCHEMBL11277134 | 1.00 | L3MBTL1 (0.36) | L3MBTL1FUCA1AMY1ASYNJ2NR1H3 | |
| SCHEMBL2046273 | 1.00 | L3MBTL1 (0.36) | L3MBTL1FUCA1AMY1ASYNJ2NR1H3 | |
| SCHEMBL5670720 | 1.00 | L3MBTL1 (0.36) | L3MBTL1FUCA1AMY1ASYNJ2NR1H3 | |
| SCHEMBL18305015 | 1.00 | L3MBTL1 (0.36) | L3MBTL1FUCA1AMY1ASYNJ2NR1H3 | |
| SCHEMBL13079298 | 1.00 | L3MBTL1 (0.36) | L3MBTL1FUCA1AMY1ASYNJ2NR1H3 | |
| SCHEMBL1119069 | 1.00 | L3MBTL1 (0.36) | L3MBTL1FUCA1AMY1ASYNJ2NR1H3 | |
| SCHEMBL18940518 | 1.00 | L3MBTL1 (0.36) | L3MBTL1FUCA1AMY1ASYNJ2NR1H3 | |
| SCHEMBL17773549 | 0.87 | FUCA1 (0.33) | FUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357300-A1 | TRITERPENE SAPONIN SYNTHESIS, INTERMEDIATES AND ADJUVANT COMBINATIONS | ADJUVANCE TECHNOLOGIES, INC. (US) | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357300-A1 | TRITERPENE SAPONIN SYNTHESIS, INTERMEDIATES AND ADJUVANT COMBINATIONS | SQLE, LSS, MYD88 | L3MBTL1 4549/4885FUCA1 3490/4885AMY1A 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.